1Krediet RT. 30 years of peritoneal dialysis develop- ment: the past and the future[J]. PeTit Dial Int, 2007, 27(Suppl 2):S35-S41.
2Williams JD, Craig KJ, Topley N, et al. Peritoneal dial- ysis: changes to the structure of the peritoneal mem brane and potential for biocompatible solutions[J]. Kidney Int Suppl, 2003, (84):S158 -S161.
3Brown FG, Dent A, Hurst K, et al. Chapter 6 Peritoneal dialysis: The 34th Annual Report 2011-Data to 2010[R]. Australia:ANZDATA[2015- 11- 17]. http://www, anzdata, org. au/vl/report'2011, html (accessed 6 March 2014).
4Bargman JM, Thorpe KE, Churchill DN, et al. Peritoneal Dialysis Study Group. Relative contribution of residu- al renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study[J]. J Am Soc Nephrol, 2001, 12(10):2158-2162.
5Krishnan M, Tam P, Wu G, et al. Glucose degradation products (GDP's) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solu- tions prevent these changes[J]?Int Urol Nephrol, 2005,37 (2):409 - 418.
6Haas S, Sehmitt CP, Arbeiter K, et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral pH bicarbonate dialysis solution among chil dren undergoing automated peritoneal dialysis[J]. J Am Soe Nephrol, 2003,14(10):2632-2638.
7Santamaria B, Ucero AC, Reyero A, et aI. 3,4 Dideoxy- glueosone-3 erie as a mediator of peritoneal demesothe- lization[J]. Nephrol Dial Transplant, 2008, 23(10): 3307 - 3315.
8Nakayama M, Kawaguchi Y, Yamada K, et al. Immunohisto- chemical detection of advanced glycosylation end-prod uets in the peritoneum and its possible pathophysiolog ical role in CAPD[J]. Kidney Int, 1997,51(1):182-186.
9Pollock C. Pathogenesis of peritoneal sclerosis[J]. Int J Artif Organs, 2005, 28(2):90-96.
10Mateijsen MA, van der Wal AC, Hendriks PM, et al. Vaseu- lar and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis[J]. PeTit Dial Int, 1999, 19(6):517-525.
